Literature DB >> 10628353

Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line.

T Yasuno1, T Matsumura, T Shikata, J Inazawa, T Sakabe, S Tsuchida, T Takahata, S Miyairi, A Naganuma, T Sawada.   

Abstract

BACKGROUND: To investigate the mechanisms of cisplatin (CDDP)-resistance in neuroblastoma(NB), we established a CDDP-resistant human NB cell line, BM1R2.
MATERIALS AND METHODS: We characterized BM1R2 in terms of the susceptibilities to other anticancer agents, MDR1 and MRP expression, MYCN amplification, intracellular gultathione-S-transferase(GST-pi), metallothionein(MT) and gultathione(GSH) levels, and immunocytochemical and cytogenetic features.
RESULTS: When compared to parent BM1 line, BM1R2 exhibited a 17.0-fold resistance to CDDP and cross-resistance to other agents. MRP expression was only observed in BM1R2, whereas MDR1 was expressed in both lines. Notably higher intracellular GST-pi and MT levels were observed in BM1R2 cells. MYCN amplifications were 50 and 6 copies in BM1 and BM1R2, respectively, and additional aberrations were observed in chromosome 1 and 2 in BM1R2.
CONCLUSION: It was suggested that GST-pi and MT could exert crucial roles on CDDP-resistance in our system. BM1R2 is of great interest for investigating the mechanisms of CDDP-resistance in NB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628353

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue.

Authors:  Minako Suzuki; Hiroshi Ishikawa; Akira Tanaka; Izumi Mataga
Journal:  Hum Cell       Date:  2010-12-29       Impact factor: 4.174

2.  Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins.

Authors:  Graziele Fonseca de Sousa; Maira de Assis Lima; Débora Fernandes Custodio; Vanessa Morais Freitas; Gisele Monteiro
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.